SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-22-135208
Filing Date
2022-05-02
Accepted
2022-05-02 06:09:54
Documents
10
Period of Report
2022-06-16

Document Format Files

Seq Description Document Type Size
1 DEF 14A d340569ddef14a.htm DEF 14A 357859
2 GRAPHIC g340569g02c48.jpg GRAPHIC 31849
3 GRAPHIC g340569gra001.jpg GRAPHIC 2109
4 GRAPHIC g340569gra002.jpg GRAPHIC 1024
5 GRAPHIC g340569gra003.jpg GRAPHIC 1338
6 GRAPHIC g340569gra004.jpg GRAPHIC 1121
7 GRAPHIC g340569gra005.jpg GRAPHIC 1308
8 GRAPHIC g340569gra006.jpg GRAPHIC 955
9 GRAPHIC g340569gra007.jpg GRAPHIC 1038
10 GRAPHIC g340569gra009.jpg GRAPHIC 910
  Complete submission text file 0001193125-22-135208.txt   417573
Mailing Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618
Business Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618 (949) 409-9820
Tarsus Pharmaceuticals, Inc. (Filer) CIK: 0001819790 (see all company filings)

IRS No.: 814717861 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39614 | Film No.: 22879243
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences